State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China.
State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping 1, Lanzhou, Gansu, 730046, PR China.
Vet Microbiol. 2018 Jun;219:40-48. doi: 10.1016/j.vetmic.2018.04.007. Epub 2018 Apr 5.
Bluetongue virus (BTV), a vector-borne pathogen, is the causative agent of bluetongue disease in ruminants. In view of the recent emergence of BTV in regions previously known to be free from the disease and/or specific serotypes or strains, optimization of the currently available vaccination strategies to control the spread of vector-borne bluetongue is crucial. The main objective of the current study was to develop a subunit vaccine candidate targeting BTV-16, a strain previously isolated in China from sheep with obvious clinical signs. To this end, five polyhistidine-tagged recombinant proteins (BTV-16 VP2, VP3, VP7, NS2 and a truncated version of VP5 (VP5-41amino acids) were expressed using the baculovirus or Escherichia coli expression system for characterization of protective activity. To determine ovine and murine immune responses to the five proteins, sheep and mice were immunized twice at 4- and 2-week intervals, respectively, with one of two different protein combinations in Montanide ISA201 VG adjuvant or placebo. Data from the competitive enzyme linked immunosorbent assay revealed significantly higher antibody titers in immunized than control animals. Expressed VP5 and NS2 induced a protein-specific humoral response. Interestingly, a serum neutralization test against the BTV-1 serotype showed promising cross-serotype immune response by the vaccine. Based on the collective data, we suggest that these recombinant purified proteins present promising candidates for the design of effective novel vaccines against BTV.
蓝舌病病毒（BTV）是一种经媒介传播的病原体，是反刍动物蓝舌病的病原体。鉴于 BTV 最近在以前无病地区和/或特定血清型或株出现，优化目前可用于控制媒介传播蓝舌病传播的疫苗接种策略至关重要。本研究的主要目的是开发针对 BTV-16 的亚单位疫苗候选物，BTV-16 是以前在中国从有明显临床症状的绵羊中分离出来的一种株。为此，使用杆状病毒或大肠杆菌表达系统表达了五个组氨酸标签的重组蛋白（BTV-16 VP2、VP3、VP7、NS2 和 VP5 的截短版本（VP5-41 个氨基酸），以表征保护活性。为了确定绵羊和小鼠对这五种蛋白的免疫反应，绵羊和小鼠分别在 4 周和 2 周的间隔时间内用 Montanide ISA201 VG 佐剂中的两种不同蛋白组合之一或安慰剂进行两次免疫。竞争性酶联免疫吸附试验的数据显示，免疫动物的抗体滴度明显高于对照动物。表达的 VP5 和 NS2 诱导了蛋白特异性体液反应。有趣的是，针对 BTV-1 血清型的血清中和试验显示疫苗具有有希望的交叉血清型免疫反应。基于这些数据，我们认为这些重组纯化蛋白是设计针对 BTV 的有效新型疫苗的有前途的候选物。
